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Evans syndrome (ES) is a rare autoimmune disorder deﬁned
by the combination of idiopathic thrombocytopenic
purpura (ITP) and autoimmune hemolytic anemia (AIHA),
occasionally with immune neutropenia, in the absence of
known underlying etiology.1,2 ITP and AIHA may occur
simultaneously or sequentially. The peak age of manifesta-
tion ranges between 5.5 and 7.7 years and both the sexes
are equally affected.1 ES has a chronic relapsing course with
occasional remission; its clinical features reﬂect those of
hemolytic anemia (pallor, lethargy, and jaundice) and
thrombocytopenia (epistaxis, cutaneous or gingival bleed-
ing, hematuria, menorrhagia, and fatigue). First-line thera-
py of ES is usually done with corticosteroids alone or in
combination with intravenous immunoglobulin (IVIG), al-
though the management of ES remains a challenge.1,2
Patients with ITP have an increased risk of perioperative
bleeding.3,4 Since the ﬁrst report of a successful open
cardiac surgery in ITP patients3,5 in the 1980s, no micro-
surgical free ﬂap procedures have been described in ES-
patients so far.
In this report, we describe and discuss the ﬁrst successful
case of microvascular reconstruction of the mandible with
free bone ﬂaps in a patient with ES.
Case Report
A 12-year-old white woman was diagnosed ES in 2003.
Initially, a cyclic corticosteroid therapy consisting of 10-day
course of prednisone (25 mg, twice daily) was adopted
depending on the platelets (PLT) count. The therapy failed
to control recurrent episodes of gingival bleeding that oc-
curred during the following years.
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Abstract In this report, we describe the ﬁrst successful case of microvascular free tissue transfer in
a patient with Evans Syndrome (ES), a rare form of idiopathic thrombocytopenic purpura
(ITP) and associated autoimmune hemolytic anemia (AIHA). Microvascular surgery in
the setting of ES is likely to have higher complication rates because of the increased risk
of postoperative bleeding and free ﬂap thrombosis. The case presented here opens up
to the feasibility of microvascular reconstruction of patients with coagulation disorders
like ES. Every effort should be made to control for hemolytic, thrombocytopenic, and
thrombophilic states associated with ES. In the absence of evidence-based treatment
guidelines for ES, personalized treatment protocols with high-dose corticosteroids,
immunoglobulin, and postoperative anticoagulation regimen are highly recommended.
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In January 2007, at the age of 16 years, she was presented
at our department with a fast-growing painless mass of the
left mandibular body (►Fig. 1). This lesion caused teeth
crowding, malocclusion, and facial deformity. Oral and dental
care had been neglected for a long time owing to the risk of
further hemorrhages. Computed tomographic scans showed a
14-cm-wide multiloculated bone lesion extending from the
left mandibular angle to the contralateral premolar region,
with cortical interruption (►Fig. 1). Blood tests revealed a
severe thrombocytopenia (PLT 26  109/L) and a prolonged
activated partial thromboplastin time (1.7 ratio) that was
linked to the presence of antiphospholipid antibodies (aPL).
AIHA disorder proved mild. A cushingoid statewas present as
a result of the chronic steroid therapy that was tapered and
then interrupted. The patient was started on a 4-day course of
dexamethasone (1-day upload course of 40 mg/four times
daily, then 40 mg/four times daily), with a rapid increase of
the PLT count (243  109/L), which remained stable above
100  109/L for several weeks. Within a normalized risk of
bleeding, the patient underwent a biopsy of the bone lesion.
On the basis of the pathology report, a conclusive diagnosis of
aggressive central giant cell granuloma (CGCG) was made,
once hyperparathyroidism was ruled out. Furthermore, den-
tal treatments were safely performed on an outpatient basis
before the patient underwent subtotal mandibulectomy in
June 2007. The 14-cm-long mandibular defect was immedi-
ately reconstructed with an osteomuscular ﬁbular bone ﬂap
harvested from the right leg. The peroneal artery and accom-
panying veinswere anastomosed to the right facial artery and
vein and to the external jugular vein (►Fig. 2). No life-
threatening intraoperative bleeding occurred. At the end of
the procedure, the PLT count was 138  109/L and hemoglo-
bin was 8.90 g/L. Postoperative AIHA and ITP were controlled
with the use of methylprednisolone intravenous dextran
40,000 PM at a dose of 20 mL/h and low-molecular–weight
heparin (2,850 IU subcutaneous) were administered daily for
5 days. The patient’s postoperative coursewas uneventful and
the patient was discharged 18 days after surgery with a PLT
count of 137  109/L.
The patient remained stable without major bleeding up to
the age of 18 when she was asked for a full-arch dental
rehabilitation (►Fig. 3). After consultation with the Hematol-
ogy Department, a second vascularized ﬁbula ﬂap was
planned to reconstruct the alveolar bone region and ﬁll-up
the vertical gap of the mandible. In November 2009, the
patient underwent free ﬁbula ﬂap transfer from the left leg.
Fig. 1 Preoperative. (A) Frontal view of the patient: gross deformity of
the mandible and facial asymmetry due to abnormal tumor-related
skeletal growth (white arrow). (B) Computed tomography (three-
dimensional computed tomography): extensive bone lesion involving
the entire horizontal branch of the mandible; note the multiple
fenestrations of the outer cortical plate (white arrow). (C) Intraoral
view: obliteration of the left mucosal vestibule, teeth crowding (white
arrow), and severe periodontal disease (white arrowhead).
Fig. 2 First operation. (A) Specimen: intraoperative conﬁrmation of
the margins of mandible resection onto the stereolithographic model
(white arrow). (B) Fibula ﬂap: veriﬁcation of the three-dimensional
skeletal relationships of the new mandible before ﬂap inset (white
arrow). (C) View of the reconstructed mandible after ﬂap inset and
completion of microvascular anastomoses (white arrow). Two 2.0-mm
locking plates (2.0-mm Mandible Locking Plates System, Synthes, Inc.,
West Chester, PA) were used to ﬁx each bone segment and the
mandibular stumps (white arrowhead).
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Surgery was performed by the same operators (A.B., A.F., S.V.,
and G.B.), and the previously adopted operative and medical
protocols were used. Postoperative course was uneventful
and the patient was discharged 14 days after surgery with a
PLT count of 146 109/L. Two more surgeries were required
for the completion of the dental rehabilitation protocol. The
patient was free of disease at 3-year follow-up without any
signs of AIHA and ITP (►Fig. 4).
Discussion
ES is a rare form (1%) of ITP and associated AIHA.2 The
increased risk of bleeding and life-threatening hemorrhages
that is secondary to the accelerated PLT destruction caused by
antiplatelet antibodies1,6 usually contraindicate major sur-
gery in ES patients.
In the present case both diagnosis and treatment of the
mandibular lesion have been postponed formore than 3 years
since the initiation of the disease process, due to the fear of
bleeding.
CGCG of the jaws is a reparative nonneoplastic, nonhyper-
parathyroidism-related process, whose treatment is usually
conservative (i.e., curettage, corticosteroid injections, calcito-
nin, and interferon alfa).7 Aggressive forms often require a
radical approach, as in this case where facial disﬁgurement
and malocclusion were present.8 Fibula is the workhorse ﬂap
in pediatric mandibular reconstruction when long defects
have to be spanned.9
Bleeding disorders and thrombophilia are considered
among the most relevant factors that can inﬂuence the
outcome of microsurgical reconstruction.10–12
A narrative review of the available literature turned out
few case reports describing free ﬂap failure in patients with
undiagnosed hypercoagulation disorders, who underwent
major head and neck reconstruction.13–17 These authors state
that hypercoagulation disorders may represent an indepen-
dent factor affecting free ﬂap success.18
A recent internal survey from Wang et al19 found an
increased risk of free ﬂap failure also in patients with known
thrombophilic conditions; nonetheless, microsurgical recon-
struction was not contraindicated in those patients when an
Fig. 3 18-month follow-up (ﬁrst operation). (A) Frontal view of the
patient: re-established symmetry of the oval; note the shortened lower
third of the face because of insufﬁcient mandibular bone height (white
arrow). (B) Three-dimensional computed tomography: fully restored
mandibular bone buttressing and complete bone union between the
ﬁbular segments and the residual mandibular stumps (white arrow).
(C) Intraoral view: stable mucosal healing of the reconstructed
mandible.
Fig. 4 3-year follow-up (second operation). (A) Frontal view of the
patient: improved symmetry of the lower third of the face following
augmentation of the mandible with the second ﬁbula ﬂap and implant-
supported prosthetic restoration (white arrow). (B) Three-dimensional
computed tomography: the initial ﬁbula ﬂap (basal bone) (black arrow)
and the second one (alveolar bone) (black arrowhead) fused together
to provide a nearly natural shape of the reconstructed mandible. (C)
Intraoral view: healthy peri-implant (lower jaw) and periodontal seal
(upper jaw); of note, the peri-implant seal was obtained by means of
secondary split-thickness skin grafting at the time of second-stage
implant surgery (white arrow).
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accurate preoperative work-up and perioperative treatment
of thrombophilia is performed, according to the American
guidelines of College of Chest Physicians.20
Thrombophilia increases the risk of thrombosis and free
ﬂap failure also in ES patients, especially when prolonged
activated partial thromboplastin time is present, which is
often related to aPLs, as in this case.2,6
A variety of preoperative treatment strategies have been
proposed in ES to boost PLT count before intervention and to
minimize perioperative hemorrhages, including preoperative
or concomitant splenectomy, corticosteroids medication,
preoperative and/or postoperative IVIG, PLT transfusion,
and immunosuppressive agent (danazol).21,22 First-line ther-
apy for nonemergent indications is based on corticosteroids
and/or IVIG. In emergent setting, blood and PLT transfusion
may be administered to alleviate symptoms. Initial therapy
for nonemergent indications is based on orally prednisone (1
mg/kg daily) for 3 or 4 weeks or prednisolone (1–4 mg/kg
daily).
Only 10 to 30% of ES patients on long-term corticosteroid
therapy achieve stable remission and thrombocytopenia
usually recurs in most cases after discontinuation.1,2 When
steroids are ineffective or toxic, the most common ﬁrst-line
therapy is concomitantly used of IVIG (0.4 g/kg/daily for 4
days).1 Second-line therapy includes immunosuppressive
agents (cyclosporine, mycophenolate mofetil, and danazol),
the monoclonal antibody rituximab and chemotherapy (vin-
cristine). Splenectomy is recommended in persistent ITP
patient in case of a remission period less than 1 year after
diagnosis, when the PLT count is consistently less than
20,000  109/L or when the patient is not responding to
therapy21; long-term remission in ES after splenectomy is less
frequent than in uncomplicated ITP. Stem cell transplantation
offers a further chance for severe and refractory cases.1
Prolonged activated partial thromboplastin time in ITP
patients is often related to aPL presence and give rise to a
thrombotic risk (arterial and venous thrombosis, recurrent
fetal loss).2,6
As no successful experience is reported in ES patients
who are candidates for major head and neck surgical
resections and microsurgical reconstructions, we followed
the recommendations of the British Haematology task
force23 and maintained PLT count above 100,000  109/L
using perioperative high-dose corticosteroids.2 Of impor-
tance, PLT counts should not exceed 200,000  109/L to
minimize the associated thrombophilic risk. High-dose
dexamethasone was effective to boost PLT count before
intervention. Immunomodulating agents and IVIG were
also prepared to be used in case of necessity, to diminish
the substantial risk of thrombosis associated with aPLs in
the postoperative. Nevertheless, thromboprophylaxis with
daily subcutaneous injection of low-molecular-weight
heparin was enough to prevent from vessel thrombosis
and ﬂap failure in the present case.
In conclusion, microvascular free ﬂap surgery is feasible
also in ES patients with autoimmune clotting disorders. ES
patients who are candidates tomicrosurgical reconstructions
should be carefully assessed for their hemolytic, thrombocy-
topenic, and thrombophilic states and treated accordingly to
minimize the risk of free ﬂap failure.
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